share_log

Earnings Call Summary | Imunon(IMNN.US) Q1 2024 Earnings Conference

Earnings Call Summary | Imunon(IMNN.US) Q1 2024 Earnings Conference

财报电话会议摘要 | Imunon (IMNN.US) 2024 年第一季度财报会议
富途资讯 ·  05/14 06:26  · 电话会议

The following is a summary of the Imunon, Inc. (IMNN) Q1 2024 Earnings Call Transcript:

以下是Imunon, Inc.(IMNN)2024年第一季度财报电话会议记录摘要:

Financial Performance:

财务业绩:

  • Imunon reported a net loss for Q1 2024 of $4.9 million or $0.52 per share, a decrease from a net loss of $5.6 million or $0.68 per share for the same period last year.

  • Operating expenses were $5 million, marking a decrease of 12% from last year, with R&D expenses amounting to $3.3 million.

  • Cash and investment balance as of March 31, 2024, stood at $9.8 million.

  • The costs associated with PlaCCine DNA vaccine technology platform were $1.6 million for Q1 2024, which is higher compared to $1.4 million in Q1 2023.

  • Costs associated with developing in-house pilot manufacturing capabilities decreased to $300,000 in Q1 2024, from $600,000 in Q1 2023.

  • General and administrative expenditures reduced to $1.7 million in Q1 2024, primarily due to lowered non-cash compensation expense, employee-related costs, consulting and legal fees, as well as reduced premiums on their D&O insurance.

  • Imunon报告称,2024年第一季度的净亏损为490万美元,合每股亏损0.52美元,低于去年同期的净亏损560万美元或每股亏损0.68美元。

  • 运营支出为500万美元,比去年下降了12%,研发费用为330万美元。

  • 截至2024年3月31日,现金和投资余额为980万美元。

  • 2024年第一季度与PlacCine DNA疫苗技术平台相关的成本为160万美元,高于2023年第一季度的140万美元。

  • 与开发内部试点制造能力相关的成本从2023年第一季度的60万美元降至2024年第一季度的30万美元。

  • 2024年第一季度的一般和管理支出减少至170万美元,这主要是由于非现金薪酬支出、员工相关成本、咨询和律师费的降低,以及其D&O保险的保费降低。

Business Progress:

业务进展:

  • Imunon is advancing its lead investigational immunotherapy for ovarian cancer and anticipates reporting Phase 2 top-line results by mid-2024. A second study, conducted by Breakthrough Cancer Foundation and MD Anderson Cancer Center with IMNN-001 is also planned.

  • The company received FDA approval for a Phase 1 protocol for a seasonal COVID-19 booster with enrollment underway.

  • Imunon has welcomed new CEO, Stacy Lindborg, a veteran in the industry with over 30 years of experience.

  • The focus for the future includes advancing TheraPlas and PlaCCine technology platforms, with potential applications in intraperitoneal cancers and various viral pathogens.

  • Imunon正在推进其主要的卵巢癌研究性免疫疗法,并预计到2024年中期报告2期的顶级结果。突破癌症基金会和医学博士安德森癌症中心还计划进行第二项针对 IMNN-001 的研究。

  • 该公司获得美国食品药品管理局批准了季节性 COVID-19 加强剂的第 1 阶段协议,注册正在进行中。

  • Imunon迎来了新任首席执行官史黛西·林德博格,她是该行业的资深人士,拥有30多年的经验。

  • 未来的重点包括推进TheraPLAS和PlacCine技术平台,其潜在应用于腹膜内癌症和各种病毒病原体。

More details: Imunon IR

更多详情: Imunon IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.

提示:欲了解更多详情,请访问投资者关系网站。本文仅供投资者参考,不构成任何投资建议。

译文内容由第三方软件翻译。


以上内容仅用作资讯或教育之目的,不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。
    抢沙发